1. Scrip
  2. >>Business
  3. >>Strategy

Value Transfusion: Vitex Merges with Panacos Pharmaceuticals

 
• By Mary Stuart

V.I. Technologies Inc. (Vitex), a developer of pathogen inactivation technologies for donor blood, has agreed to acquire privately-held Panacos Pharmaceuticals Inc. in a stock swap valued at approximately $26.25 million at current stock prices. Superficially, the deal appears to be fairly typical pipeline building: Vitex has a late-stage blood safety product, Inactine, in Phase III clinical trials, and Panacos Pharmaceuticals offers a Phase I anti-HIV compound, which is in line with VI Technologies' expertise in blood-borne infectious diseases. But the deal is really about value creation, as Vitex, along with all others in the pathogen inactivation market, has taken too long to get its product to the market.

V.I. Technologies Inc. (Vitex), a developer of pathogen inactivation technologies for donor blood, has agreed to acquire privately-held Panacos Pharmaceuticals Inc. in a stock swap valued at approximately $26.25 million at current stock prices. [See Deal]. Panacos shareholders will hold 31.5% of the new company after the merger, subject to the approval of shareholders by the end of August. Vitex shareholders will own the remaining 68.5%. Superficially, the deal appears to be fairly typical pipeline building: Vitex has a late-stage blood safety product, Inactine, in Phase III clinical trials, and Panacos Pharmaceuticals offers a Phase I anti-HIV compound, which is in line with VI Technologies' expertise in blood-borne infectious diseases.

But the deal is really about value creation, or rather value salvation, as Vitex, along with all others in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Sanofi Flies The Flag For France

 
• By Kevin Grogan

The Paris-headquartered giant has put the spotlight on its extensive investments at home.

Some CAR-Ts Are Thriving While Others Are Falling Behind. Why?

 
• By Alaric DeArment

With Gilead reporting that both of its approved CAR-Ts saw sales declines as other products saw growth, a mixture of different competitive headwinds seems to be behind the disparities.

Finance Watch: Lilly Toes The $1 Trillion Valuation Line

 
• By Mandy Jackson

Public Company Edition: Lilly’s obesity franchise makes it the highest-valued health care company in the US. Also, Genmab accesses $4.5bn to fund its $8bn Merus buy, Moderna locks in a $1.5bn credit facility and Ionis sells $700m worth of notes.

Sibeprenlimab’s US Accelerated Approval Drives IgAN Competition Forward

 
• By Lisa Takagi

Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.

More from Business

Sibeprenlimab’s US Accelerated Approval Drives IgAN Competition Forward

 
• By Lisa Takagi

Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.

Lundbeck Concedes Avadel Bidding War, But Remains On The Hunt

 
• By Manas Mishra

Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.